Ohio State study tracks veteran outcomes following psychedelic treatment
A study of 113 U.S. veterans receiving ibogaine and 5-MeO-DMT suggests symptom reduction over nine months, though researchers call for controlled trials to confirm findings.
Researchers at The Ohio State University’s Center for Psychedelic Drug Research and Education have published findings in the journal Chronic Stress tracking 113 U.S. military veterans who received psychedelic-assisted treatments. The participants, supported by grants from the nonprofit Veterans Exploring Treatment Solutions (VETS), underwent treatment involving ibogaine and 5-MeO-DMT in Mexico.
Over the nine-month follow-up period, participants reported statistically significant reductions in symptoms of post-traumatic stress disorder (PTSD), depression, and anxiety. The study also noted an increase in psychological flexibility, which researchers identified as a potential indicator of ongoing symptom improvement.
However, the study authors cautioned against drawing definitive conclusions regarding efficacy. Lead researcher Alan K. Davis noted that the findings require verification through controlled clinical trials with standardized protocols and direct medical monitoring. Because the study lacked a comparison group and utilized both substances simultaneously, the specific therapeutic contribution of each remains unknown.
Moving forward, the research team advocates for rigorous testing to determine the safety and long-term viability of these substances as clinical treatment options for veterans.